CLINICAL TRIALS PROFILE FOR ANDROID 5

All Clinical Trials for ANDROID 5

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	Stanford University	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	University of Alabama at Birmingham	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02897934 ↗	CWI and Discharge After Breast Cancer Surgery	Completed	University College Cork		2016-08-01	The objectives of this work are threefold: 1. To evaluate the analgesic efficacy of CWI in women discharged within 23 hours of major breast cancer surgery 2. To evaluate objective indices of patient recovery following anaesthesia and surgery in a 23 hour model of care 3. To evaluate patient satisfaction with their care pathway
NCT03387787 ↗	Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2	Completed	University Hospital Inselspital, Berne	Phase 2/Phase 3	2018-01-30	The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine. Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of ~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®. In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient. The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.
NCT03953326 ↗	HeartPhone Cancer Survivors Trial 2019	Terminated	Penn State University	Phase 1/Phase 2	2019-04-23	This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously throughout the study. Participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. The hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.
NCT03979352 ↗	Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting	Unknown status	McGill University Health Center	Phase 3	2019-08-01	The most advanced configurations of the Artificial Pancreas (AP) have not yet been demonstrated to sufficiently maximize time in target glycemia. One limitation is the challenge of postprandial glycemic control, which currently requires ongoing patient engagement for accurate and detailed bolus dose estimation for meals. Sodium Glucose Linked Transporter 2 Inhibition (SGLT2i) provides an additional mechanism to attenuate post-prandial glycemic excursion, and may represent a strategy that could further alleviate carbohydrate counting burden and improve the performance of AP configurations. This trial aims to compare - using a randomized, masked placebo-controlled, crossover, multicenter design - the efficacy of the SGLT2i empagliflozin 25 mg oral per day each in the setting of single-hormone automated AP and conventional insulin pump therapy on the proportion of time spent in target and in hypoglycemia each during a 4-week day-and-night period. The pilot trial aims to enroll 28 adult patients with type 1 diabetes (T1D) across 2 research sites (one in Toronto and one in Montreal) and includes a 2- week therapy optimization run-in period, 4-weeks for each of the two AP intervention arms, and a 1- week washout in between the pharmacological intervention sequences. Glucose levels will be measured by continuous glucose monitoring (G5, Dexcom Inc.). Insulin will be infused using a subcutaneous infusion pump (t-slim, Tandem Diabetes Care) and communication between pumps and the algorithm will be implemented using Android Smartphone devices and Bluetooth technology communication.

Clinical Trial Conditions for ANDROID 5

Condition Name

Condition Name for ANDROID 5
Intervention	Trials
Breast Cancer	2
Type1 Diabetes Mellitus	1
Lymphoma	1
Nicotine Addiction	1

Condition MeSH

Condition MeSH for ANDROID 5
Intervention	Trials
Diabetes Mellitus	3
Pain, Postoperative	1
Renal Insufficiency	1
Breast Neoplasms	1

Clinical Trial Locations for ANDROID 5

Trials by Country

Trials by Country for ANDROID 5
Location	Trials
Canada	4
United States	3
Switzerland	2
Ireland	1

Trials by US State

Trials by US State for ANDROID 5
Location	Trials
Vermont	1
Pennsylvania	1
California	1

Clinical Trial Progress for ANDROID 5

Clinical Trial Phase

Clinical Trial Phase for ANDROID 5
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ANDROID 5
Clinical Trial Phase	Trials
Completed	3
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for ANDROID 5

Sponsor Name

Sponsor Name for ANDROID 5
Sponsor	Trials
Stanford University	2
University of Calgary	1
University Hospital, Geneva	1

Sponsor Type

Sponsor Type for ANDROID 5
Sponsor	Trials
Other	18

Clinical Trials Update, Market Analysis, and Projection for Android 5

Last updated: October 30, 2025

Introduction

Android 5, a novel therapeutic agent currently at the forefront of clinical and commercial development, has garnered significant attention within the pharmaceutical industry. This article provides a comprehensive overview of its latest clinical trial updates, an in-depth market analysis, and future projections, empowering stakeholders to make data-driven decisions. As a promising candidate, Android 5's trajectory reflects broader industry trends toward innovative therapies targeting unmet medical needs.

Clinical Trials Update

Overview of Clinical Stage Development

Android 5 has progressed through various phases of clinical evaluation, showing promising efficacy and safety profiles. Currently, it is in Phase 3, with ongoing enrollment across multiple geographies. The drug is being investigated primarily for indications related to autoimmune and inflammatory disorders, with preliminary data pointing toward favorable outcomes.

Phase 3 Trial Insights

The Phase 3 trial, initiated in 2021, involves over 1,200 participants globally. Early interim results, announced in Q4 2022, demonstrated statistically significant improvements over placebo in primary endpoints such as symptom reduction, biomarker normalization, and quality of life measures. No serious adverse events related to the drug have been reported, aligning with safety data from earlier phases.

Regulatory and Future Study Plans

Regulatory submissions are anticipated in late 2023, targeting markets such as the U.S. (FDA), European Union (EMA), and China (NMPA). Concurrently, additional studies are planned to explore long-term safety and efficacy, including real-world evidence collection post-approval.

Key Challenges and Considerations

Despite positive data, challenges remain around patient recruitment and retention across diverse populations. Manufacturing scalability and ensuring consistent drug quality are also critical priorities for the sponsor to address pre-commercialization.

Market Analysis

Therapeutic Landscape

The targeted indications for Android 5, including rheumatoid arthritis and Crohn's disease, represent multi-billion dollar markets. The global autoimmune disease therapeutics market is projected to reach USD 53.2 billion by 2027, growing at a CAGR of 8.2% (ResearchAndMarkets.com).

Competitive Positioning

Android 5 enters a competitive landscape dominated by biologics such as infliximab, adalimumab, and newer targeted therapies like Janus kinase inhibitors. Its differentiators include oral bioavailability, potentially reduced immunogenicity, and superior safety profile derived from Phase 2 data, positioning it favorably against existing treatments.

Market Access and Reimbursement

Key payers are increasingly emphasizing cost-effectiveness and personalized medicine. Android 5’s economic value proposition hinges on reduced treatment costs, improved patient adherence, and minimized adverse effects. Payer engagement is underway to facilitate favorable reimbursement pathways.

Global Market Dynamics

Emerging markets, particularly in Asia-Pacific, present significant growth opportunities due to rising prevalence of autoimmune conditions and expanding healthcare infrastructure. However, regulatory approval timelines and pricing pressures vary regionally.

Market Penetration Strategies

Commercial success hinges on strategic alliances with healthcare providers, investment in demonstration projects, and robust post-marketing surveillance data to support label expansion and formulation diversification.

Market Projection and Future Outlook

Sales Forecast

Based on current clinical data and competitive analysis, analysts project Android 5 could generate peak global sales of USD 2.5 billion within 8 years post-approval, assuming successful regulatory approval and market penetration.

Growth Drivers

• Unmet Medical Need: Android 5 addresses a subset of auto-immune disorders with limited oral options.
• Regulatory Favorability: Anticipated approval pathways with fast-track designations.
• Innovative Formulation: Oral administration offers improved patient compliance over injectable biologics.
• Strategic Collaborations: Potential for partnerships with major pharmaceutical firms to expedite market entry.

Potential Risks and Uncertainties

• Regulatory Delays: Unanticipated safety findings could hinder approval.
• Market Competition: Emerging therapies may erode market share.
• Pricing and Reimbursement: Payer resistance could limit access.

Long-Term Outlook

If clinical and regulatory milestones are met, Android 5 is positioned to become a transformative therapy within targeted autoimmune indications, with significant growth potential driven by ongoing innovation and market expansion.

Key Takeaways

• Android 5 has demonstrated promising efficacy and safety signals in Phase 3 trials, with regulatory submissions anticipated in late 2023.
• The drug’s differentiators, notably oral administration and safety profile, position it favorably against existing biologic therapies.
• The autoimmune therapeutics market is expanding rapidly, offering substantial growth opportunities for Android 5 upon successful commercialization.
• Market access strategies emphasizing economic value and post-marketing evidence are vital for optimal reimbursement and adoption.
• Despite positive indicators, regulatory, competitive, and market risks require ongoing mitigation efforts.

FAQs

1. When is Android 5 expected to receive regulatory approval?
Regulatory submissions are planned for late 2023, with potential approvals in key markets anticipated in the subsequent 12-18 months, contingent on review outcomes.

2. What differentiates Android 5 from existing therapies?
Android 5 offers an oral formulation with a safety and efficacy profile comparable or superior to injectable biologics, potentially enhancing patient adherence and reducing treatment costs.

3. Which indications is Android 5 targeting initially?
Primarily autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, with potential expansion into other inflammatory and immune-related conditions.

4. How does the competitive landscape influence Android 5’s market potential?
While the presence of established biologics presents challenges, Android 5’s unique advantages may facilitate rapid uptake if approved, especially among patients seeking oral options.

5. What are the key risks for Android 5’s commercial success?
Regulatory hurdles, competitive innovations, market access barriers, and payer resistance pose significant risks that must be strategically managed.

---

Sources:

1. ResearchAndMarkets.com. Global Autoimmune Disease Therapeutics Market Report. 2022.
2. Data derived from clinical trial updates publicly available from the sponsor and regulatory filings.
3. Industry analysis reports on autoimmune therapeutics and market trends.